Company intelligence / Profile preview

Biopharmaceutical Research Company

Ownership: Private
Development stage: Phase 1

Overview

BRC has received FDA Orphan Drug Designation for BRC-002 for Complex Regional Pain Syndrome. The company has begun dosing patients in investigator-initiated clinical trials for both BRC-001 (breast cancer supportive care) and BRC-002 (CRPS). They recently had a successful Type C CMC meeting with the FDA, advancing clinical development of multiple therapeutic candidates[2].

Therapeutic areas: OncologyRheumatologyNeurology
Modalities: Cannabinoid therapeuticsPoly-cannabinoids
Industry: Biotech

Drug pipeline

2 assets

BRC-001

1 more asset in the full pipeline.

Request access →

Partnerships

City of Hope

Beyond the preview

Go deeper on Biopharmaceutical Research Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biopharmaceutical Research Company.

Explore the full profile